Digital assessment technologies continue to hold the potential to revolutionise pro-cognitive trials in schizophrenia. These ...

Unlike other antipsychotics that treat schizophrenia, the agency approved ... “Cobenfy, we believe, will usher in a new class of medicine and will be truly transformational in a space that ...

After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

The US FDA has approved Bristol Myers Squibb’s new oral medicine, Cobenfy, for treating schizophrenia in adults. This ...

A collaborative study between researchers at the Icahn School of Medicine at Mount Sinai and Harvard Medical School has ...

However, Tian says that some individuals with schizophrenia may have a “noisy” EC, giving rise to auditory hallucinations.

Germline mutations modulate the risk of developing schizophrenia (SCZ). Much less is known about the role of mosaic somatic ...

A recent study may have cracked a crucial part of the origins of auditory hallucinations, potentially paving the way for ...

Scientists have linked neuropsychiatric disorders, such as schizophrenia and autism, to changes in many genes involved in ...

Zydus Lifesciences has received the USFDA's final approval to produce a generic version of Paliperidone extended-release ...